Intervention not reported
Dialysis at one year · adults with renal vasculitis
The intervention may leads to lower dialysis at one year (low certainty).
1 finding from 1 review
- RR 0.45 [0.29, 0.72]6 studies · 235 participantsLow
Findings
What do systematic reviews say?
1,935 questions · 1,986 findings · 260 reviews · Headline outcomes only
No studies found 503 · 25.3%GRADE not reported 76 · 3.8%Very low 593 · 29.9%Low 509 · 25.6%Moderate 241 · 12.1%High 64 · 3.2%
Antibiotics vs placebo
Remission · adults with renal vasculitis for maintenance therapy
Antibiotics showed no clear difference in remission at one year compared with placebo (low certainty).
1 finding from 1 review
- RR 1.14 [0.98, 1.33]2 studies · 111 participantsLow
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) vs placebo (3 tablets/4 times a day
Risk for at least one adverse event per patient · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) probably leads to higher adverse effects (number of participants who had at least one adverse… compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review
- Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes onlyRR 1.51 [1.17, 1.96]1 study · 134 participantsModerate
Tacrolimus vs mycophenolate mofetil to maintain remission
Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to higher number with complete or partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
- Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes onlyRR 2.01 [1.32, 3.07]1 study · 60 participantsLow
Tacrolimus vs mycophenolate mofetil to maintain remission
Complete response · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to higher number with complete response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
- Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes onlyRR 1.79 [1.11, 2.9]1 study · 60 participantsLow
Tacrolimus vs mycophenolate mofetil to maintain remission
Primary outcome: partial clinical response · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in number with partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
- Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes onlyRR 4.68 [0.58, 37.68]1 study · 60 participantsLow
Tacrolimus vs mycophenolate mofetil to maintain remission
Number with treatment failure by one year · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to lower number with treatment failure by one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
- Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes onlyRR 0.18 [0.06, 0.54]1 study · 60 participantsLow
Tacrolimus vs mycophenolate mofetil to maintain remission
Frequent relapses · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to lower number with frequent relapses by one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
- Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes onlyRR 0.28 [0.09, 0.92]1 study · 60 participantsLow
Tacrolimus vs mycophenolate mofetil to maintain remission
Number with steroid resistance by one year · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in number with steroid resistance by one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
- Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes onlyRR 0.07 [0, 1.23]1 study · 60 participantsLow
IV vs oral cyclophosphamide
Remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in continuing remission at one year compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
- Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes onlyRR 0.75 [0.19, 3.01]1 study · 50 participantsLow
NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
- no estimate extracted1 study · 45 participantsLow
Medium‐dose UVA‐1 phototherapy (50 J/cm²) vs low‐dose UVA‐1 phototherapy (20 J/cm²)
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
- no estimate extracted1 study · 44 participantsLow
NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
- no estimate extracted1 study · 35 participantsLow
Erythromycin vs placebo
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Erythromycin showed no clear difference in the proportion of participants with good or excellent rash… compared with placebo (low certainty).
1 finding from 1 review
- RR 4.02 [0.28, 56.61]2 studies · 86 participantsLow
Azithromycin vs placebo or vitamins
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Azithromycin showed no clear difference in the proportion of participants with good or excellent rash… compared with placebo or vitamins (low certainty).
1 finding from 1 review
- RR 1.02 [0.52, 2]2 studies · 119 participantsLow
Acyclovir vs placebo, vitamins, or no treatment
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Acyclovir probably leads to higher the proportion of participants with good or excellent rash… compared with placebo, vitamins, or no treatment (moderate certainty).
1 finding from 1 review
- RR 2.45 [1.33, 4.53]3 studies · 141 participantsModerate
Acyclovir + calamine + cetirizine vs calamine + cetirizine
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Acyclovir vs erythromycin
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
1 finding from 1 review
- no estimate extracted1 study · 30 participantsLow
Clarithromycin vs placebo
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Clarithromycin showed no clear difference in the proportion of participants with good or excellent rash… compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.13 [0.89, 1.44]1 study · 60 participantsModerate
Intervention not reported
Caregiver physical health status Studies (reported in comments section): Multilevel Assessment Instrument Total Score (Budin 2008).*** SF12 Physcial Component Summary Score (Northouse 2007). Higher scores indicate higher levels of physical health ... · informal caregivers of people affected by cancer
The review found no eligible studies for this question.
1 finding from 1 review
- Psychosocial interventions for informal caregivers of people living with cancer 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found